Valneva price target raised to $26 from $22 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised the firm’s price target on Valneva to $26 from $22 and keeps a Buy rating on the shares after the FDA granted accelerated approval for VLA1553, the company’s live attenuated single-shot chikungunya vaccine for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus.